Van twitter:
$QURE just in @ #CreditSuisse: DEAL STRONGLY POSITIVE, PT 76 Outperform, eliminates the need for Co. to build a potentially expensive global hematology commercial infrastructure for a single hemophilia product. The deal also provides substantial upfront capital to focus on the lead candidate in Huntington’s disease (AMT-130) and additional gene therapy candidates in the CNS and liver-directed space. Expecting stable bottom floor @ $61-65 as regular trading resumes, giving it 2-3 business days.Finally, we believe the deal signals high confidence in the ongoing AMT-130 Ph1/2 trial in HD. $SNY $IBB $XBI
2 positieve analisten, CreditSuisse en SunTrust, de rest kan er vooralsnog geen sjokola van maken met koersdoelen tussen de 58-62. Hebben al hun klanten verkocht op het overname verhaal en moeten nu iets nieuws verzinnen, altijd lastig.